Tag: technology

CANBERRA, Australia, June 11, 2026 /PRNewswire/ -- Seeing Machines Limited (AIM: SEE), the advanced computer vision technology company that designs AI-powered operator monitoring systems...

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...

Almost half of UK consumers want a Summer Black Friday Promotion, new Independent research shows*Black Friday offers, but hotter: Joybuy's Summer Black Friday offers...

KUALA LUMPUR, Malaysia, June 11, 2026 /PRNewswire/ -- CloudMile, a leading cloud and AI company in Asia, announced on June 10 the opening of...

HONG KONG, June 11, 2026 /PRNewswire/ -- At Tencent Cloud Day Hong Kong, Tencent Cloud, the cloud business of Tencent, announced a strategic collaboration with...

HEFEI, China, June 10, 2026 /PRNewswire/ -- Sungrow recently announced that its SG510HX utility string inverter (SG465HX for the Middle East region, offering equivalent...

Appointment expands consumer choice and convenience to American Standard products and solutions to Australians nationwide for both retail and commercial marketsMELBOURNE, Australia, June 11, 2026...

LOS ANGELES, June 10, 2026 /PRNewswire/ -- Prostate pleasure may be one of the few forms of pleasure men can uniquely experience. But why...

New collaboration brings Visa's global payment network to one of the largest AI platforms and aims to support seamless, secure transactions and broader AI-powered...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Toobit unveils Prediction Market, allowing traders to hedge risk and profit from crypto, financial, and global event forecasts using USDT.

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears

Establishes a regulatory-compliant, state-of-the-art Genome-Edited (GE) Crop Field Testing Facility to accelerate global commercialization.Enables comprehensive field evaluation of a diversified crop portfolio, including drought...

SYDNEY, June 11, 2026 /PRNewswire/ -- Insta360 announced Luna Ultra, its flagship gimbal camera co-engineered with Leica, built to combine professional imaging, 3-axis stabilization, and...